Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy.

The Journal of endocrinology - 1 Nov 2004

Fagin J A

Abstract excerpt

Treatment of patients with thyroid cancer is usually successful, and most patients are cured of the disease. However, we do not have effective therapies for patients with invasive or metastatic thyroid cancer if the disease is not surgically resectable and does not concentrate radio-iodine. Conventional external beam radiotherapy and chemotherapy are of marginal benefit. In other types of cancer, new therapies...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzenesulfonates
Share to Carcinoma, Medullary
Share to Carcinoma, Papillary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Niacinamide

Share to Phenylurea Compounds

Share to Phosphotransferases

Share to Pyridines

Share to Sorafenib

Source

Identifiers

PMID: 15531713
DOI: 10.1677/joe.1.05895

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy.PMID 15531713Read ↗

This is Your Thyroid on Drugs: Targetable Mutations and Fusions in Thyroid Carcinoma.Semantic proximity Read ↗

This is Your Thyroid on Drugs: Targetable Mutations and Fusions in Thyroid Carcinoma.Semantic proximity Read ↗

The Role of the Kinase Inhibitors in Thyroid CancersSemantic proximity Read ↗

Genetic mutations, molecular markers and future directions in research.Semantic proximity Read ↗

[Thyroid carcinomas: the role of systemic therapies in internal medicine].Semantic proximity Read ↗

Molecular genetics of human thyroid neoplasms.Semantic proximity Read ↗

Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.Semantic proximity Read ↗

[Molecular medicine in thyroid surgery].Semantic proximity Read ↗

Molecular genetics of thyroid and parathyroid neoplasia.Semantic proximity Read ↗

Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer.Semantic proximity Read ↗

Genetics of papillary thyroid cancer initiation: implications for therapy.Semantic proximity Read ↗

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.